BIOLINERX
Careers | Contact Us
search

About Us

Our Management

 
BioLineRx’s management team brings together seasoned executives with decades of experience in medicine, drug development, clinical studies, and financial and corporate development.  

PHILIP A. SERLIN, CPA, MBA
Chief Executive Officer

Mr. Serlin has served as our Chief Executive Officer since October 2016. From May 2009 to October 2016, Mr. Serlin served as our Chief Financial and Operating Officer. From January 2008 to August 2008, Mr. Serlin served as the Chief Financial Officer and Chief Operating Officer of Kayote Networks Inc. From January 2006 to December 2007, he served as the Chief Financial Officer of Tescom Software Systems Testing Ltd., an IT services company publicly traded in both Tel Aviv and London. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. Accounting Department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin currently serves as an external director at Vascular Biogenics Ltd. (Nasdaq:VBLT). Mr. Serlin is a CPA and holds a B.Sc. in accounting from Yeshiva University and a Master’s degree in economics and public policy from The George Washington University.

MALI ZEEVI, CPA
Chief Financial Officer

Ms. Zeevi has served as our Chief Financial Officer since October 2016. Prior to becoming Chief Financial Officer, Ms. Zeevi served as our Senior Director of Finance and Reporting beginning in 2011 and as our Director of Finance and Reporting beginning in 2009. Before joining BioLineRx, Ms. Zeevi was employed by Tescom Software Systems Testing Ltd., her last position there being Vice President Finance. Ms. Zeevi also served as a CPA at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited. She holds a B.A. in business and accountancy from the College of Management Academic Studies in Israel.

hillit

HILLIT MANNOR SHACHAR, MD, MBA, MSFS
Vice President Business Development

Hillit Mannor Shachar, MD, MBA, MSFS, became our Vice President Business Development in April 2018 and is responsible for our business development, commercialization of assets and pipeline strategy. Dr. Shachar joins the Company with over 15 years of experience in senior business development, corporate development and venture capital positions in the life sciences field. Her recent experience has included service as Vice President Business Development of Pluristem Therapeutics (NASDAQ:PSTI). In addition, Dr. Shachar has served at several life science companies and venture capital funds, including Apax Partners, West Pharmaceuticals, Nektar Therapeutics, Orex Computed Radiography and Kodak. Dr. Shachar received her B.A. and M.D. from Northwestern University, her M.S.F.S. from Georgetown University School of Foreign Service and her MBA from the Kellogg Recanati School of Management at Tel Aviv University.

ABI VAINSTEIN-HARAS, MD
Vice President Clinical and Medical Affairs

Abi Vainstein-Haras, M.D., has served as our Vice President Clinical and Medical Affairs since January 2017. From June 2014 to January 2017, Dr. Vainstein-Haras served as our Senior Medical Director responsible for the clinical development of all our clinical phase projects. Prior to joining the Company, from 2012 to 2014, she served as the Director and Clinical Program Leader for COPAXONE® at Teva, and from 2007 to 2012, she served in several medical positions in Innovative R&D at Teva. Dr. Vainstein-Haras holds an M.D. from University of Buenos Aires and is licensed to practice medicine in Israel.

ELLA SORANI, PhD
Vice President Research and Development

Ella Sorani, Ph.D., has served as our Vice President Development since February 2017. Before joining BioLineRx, from 2000 through 2016, Dr. Sorani served in a number of management positions in the global R&D division at Teva Pharmaceutical Industries Ltd. In her most recent position as Senior Director and Global Project Leader, Dr. Sorani led the development of one of Teva’s leading innovative late stage compounds. Dr. Sorani holds a B.Sc. in chemistry and an M.Sc. and Ph.D. in pharmacology, all from Tel Aviv University.